19,226 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by CenterBook Partners LP

CenterBook Partners LP purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 19,226 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,518,000.

Other hedge funds have also modified their holdings of the company. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares during the period. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ANI Pharmaceuticals by 30.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 253 shares during the period. Finally, Federated Hermes Inc. acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $93,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $81.20 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The business has a 50-day moving average of $79.35 and a 200-day moving average of $79.37. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 20.56 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a fifty-two week low of $61.17 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares in the company, valued at $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the transaction, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 80,178 shares of company stock valued at $6,256,052. 8.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ANIP shares. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.